Advances in the biology and genetics of the podocytopathies implications for diagnosis and therapy

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 2, 2009, Pages 201-216

  Barisoni, Laura ^a   Schnaper, H William ^b   Kopp, Jeffrey B ^c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CHLORAMBUCIL; CYCLOSPORIN A; CYTOPLASM PROTEIN; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUINDOSTATIN; GC 1008; ISOTRETINOIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PIRFENIDONE; PREDNISONE; PROTEIN; RAPAMYCIN; RITUXIMAB;

APOPTOSIS; BIOLOGY; CELL CYCLE ARREST; CELL DAMAGE; CELL DEATH; CELL DEDIFFERENTIATION; CELL FUNCTION; CELL MEMBRANE; CLINICAL TRIAL; COLLAPSING GLOMERULOPATHY; CYTOPLASM; CYTOSKELETON; DIAGNOSTIC ACCURACY; DIAPHRAGM; ELECTRON MICROSCOPY; FOCAL GLOMERULOSCLEROSIS; GENE MUTATION; GENETIC SUSCEPTIBILITY; GENETICS; GLOMERULOPATHY; HUMAN; INFECTION; KIDNEY DISEASE; KIDNEY GRAFT; MECHANICAL STRESS; MESANGIUM SCLEROSIS; MICROSCOPY; MORPHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PODOCYTE; PODOCYTOPATHY; PROTEIN EXPRESSION; REVIEW; TAXONOMY;

APOPTOSIS; CELL DIFFERENTIATION; CELL PROLIFERATION; HUMANS; KIDNEY DISEASES; MUTATION; PODOCYTES;

EID: 60149107051     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (109)

1. Barisoni L, Schnaper HW, Kopp JB. A proposed taxonomy for the podocytopathies: a reassessment of the primary nephrotic diseases. Clin J Am Soc Nephrol. 2007;2:529-542.
2. Niaudet P, Gubler MC. WT1 and glomerular diseases. Pediatr Nephrol. 2006;21:1653-1660.
3. Yang Y, Jeanpierre C, Dressier GR, Lacoste M, Niaudet P, Gubler MC. WT1 and PAX-2 podocyte expression in Denys-Drash syndrome and isolated diffuse mesangial sclerosis. Am J Pathol. 1 999;1 54:181-1 92.
4. Barisoni L, Kriz W, Mundel P, D'Agati V. The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HlV-associated nephropathy. J Am Soc Nephrol. 1999;10:51-61.
5. Srichai MB, Konieczkowski M, Padiyar A, et al. A WT1 co-regulator controls podocyte phenotype by shuttling between adhesion structures and nucleus. J Biol Chem. 2004;279:14398-14408.
6. Yang Y, Gubler MC, Beaufils H. Dysregulation of podocyte phenotype in idiopathic collapsing glomerulopathy and HlV-associated nephropathy. Nephron. 2002;91:416-423.
7. Wagner KD, Wagner N, Guo JK, et al. An inducible mouse model for PAX2-dependent glomerular disease: insights into a complex pathogenesis. Curr Biol. 2006;16:793-800.
8. Rascle A, Suleiman H, Neumann T, Witzgall R. Role of transcription factors in podocytes. Nephron Exp Nephrol. 2007;106:e60-e66.
9. Rohr C, Prestel J, Heidet L, et al. The LlM-homeodomain transcription factor Lmx1b plays a crucial role in podocytes. J Clin Invest. 2002;109:1073-1082.
10. Suleiman H, Heudobler D, Raschta AS, et al. The podocyte-specific inac- tivation of Lmx1b, Ldb1 and E2a yields new insight into a transcriptional network in podocytes. Dev Biol. 2007;304:701-712.
11. Quaggin SE, Schwartz L, Cui S, et al. The basic-helix-loop-helix protein pod1 is critically important for kidney and lung organogenesis. Development. 1999;126:5771-5783.
12. Sadl V, Jin F, Yu J, et al. The mouse Kreisler (Krml1/MafB) segmentation gene is required for differentiation of glomerular visceral epithelial cells. Dev Biol. 2002;249:16-29.
13. Ross MD, Martinka S, Mukherjee A, Sedor JR, Vinson C, Bruggeman LA. Math6 expression during kidney development and altered expression in a mouse model of glomerulosclerosis. Dev Dyn. 2006;235:3102-3109.
14. Shi YF, Fong CC, Zhang Q, et al. Hypoxia induces the activation of human hepatic stellate cells LX-2 through TGF-beta signaling pathway. FEBS Lett. 2007; 581:203-210.
15. Ding M, Cui S, Li C, et al. Loss of the tumor suppressor Vhlh leads to upregulation of Cxcr4 and rapidly progressive glomerulonephritis in mice. Nat Med. 2006;12:1081-1087.
16. Maxwell P. HlF-1: an oxygen response system with special relevance to the kidney. J Am Soc Nephrol. 2003;14:2712-2722.
17. Kanjanabuch T, Ma LJ, Chen J, et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int. 2007;71:1232-1239.
18. Moreno-Manzano V, Mampaso F, Sepulveda-Munoz JC, et al. Retinoids as a potential treatment for experimental puromycin-induced nephrosis. Br J Pharmacol. 2003;139:823-831.
19. Vaughan MR, Pippin JW, Griffin SV, et al. ATRA induces podocyte differentiation and alters nephrin and podocin expression in vitro and in vivo. Kidney Int. 2005;68:133-144.
20. Bastien J, Rochette-Egly C. Nuclear retinoid receptors and the transcription of retinoid-target genes. Gene. 2004;328:1-16.
21. Niranjan T, Bielesz B, Gruenwald A, et al. The Notch pathway in podocytes plays a role in the development of glomerular disease. Nat Med. 2008;14:290-298.
22. Waters AM, Wu MY, Onay T, et al. Ectopic notch activation in developing podocytes causes glomerulosclerosis. J Am Soc Nephrol. 2008;19:1139-1157.
23. Nagata M, Kriz W. Glomerular damage after uninephrectomy in young rats, ll: mechanical stress on podocytes as a pathway to sclerosis. Kidney Int. 1992;42:148-160.
24. Nagata M, Scharer K, Kriz W. Glomerular damage after uninephrectomy in young rats. l. Hypertrophy and distortion of capillary architecture. Kidney Int. 1992;42:136-147.
25. Kestila M, Lenkkeri U, Mannikko M, et al. Positionally cloned gene for a novel glomerular protein-nephrin-is mutated in congenital nephrotic syndrome. Mol Cell. 1998;1:575-582.
26. Boute N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet. 2000;24:349-354.
27. Kriz W. Ontogenetic development of the filtration barrier. Nephron Exp Nephrol. 2007;106:e44-e50.
28. Kim JM, Wu H, Green G, et al. CD2-associated protein haploinsufficiency is linked to glomerular disease susceptibility. Science. 2003;300:1298-1300.
29. Lowik MM, Groenen PJ, Pronk l, et al. Focal segmental glomerulosclerosis in a patient homozygous for a CD2AP mutation. Kidney Int. 2007;72:1198-1203.
30. Shih NY, Li J, Karpitskii V, et al. Congenital nephrotic syndrome in mice lacking CD2-associated protein. Science. 1999;286:312-315.
31. Shih NY, Li J, Cotran R, Mundel P, Miner JH, Shaw AS. CD2AP localizes to the slit diaphragm and binds to nephrin via a novel C-terminal domain. Am J Pathol. 2001;159:2303-2308.
32. Asanuma K, Campbell KN, Kim K, Faul C, Mundel P. Nuclear relocation of the nephrin and CD2AP-binding protein dendrin promotes apoptosis of podocytes. Proc Natl Acad Sci U S A. 2007;104:10134-10139.
33. Endlich N, Kress KR, Reiser J, et al. Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol. 2001;12:413-422.
34. Khoshnoodi J, Sigmundsson K, Ofverstedt LG, et al. Nephrin promotes cell-cell adhesion through homophilic interactions. Am J Pathol. 2003;163:2337-2346.
35. Kalluri R. Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol. 2006;17:2383-2389.
36. Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding alpha- actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet. 2000;24:251-256.
37. Weins A, Schlondorff JS, Nakamura F, et al. Disease-associated mutant alpha-actinin-4 reveals a mechanism for regulating its F-actin-binding affinity. Proc Natl Acad Sci U S A. 2007;104:16080-16085.
38. Dandapani SV, Sugimoto H, Matthews BD, et al. Alpha-actinin-4 is required for normal podocyte adhesion. J Biol Chem. 2007;282:467-477.
39. Yanagida-Asanuma E, Asanuma K, Kim K, et al. Synaptopodin protects against proteinuria by disrupting Cdc42:lRSp53:Mena signaling complexes in kidney podocytes. Am J Pathol. 2007;171:415-427.
40. Murphy-Ullrich JE. The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? J Clin Invest. 2001;107:785-790.
41. Vogelmann SU, Nelson WJ, Myers BD, Lemley KV. Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol. 2003;285:F40-F48.
42. Kreidberg JA, Donovan MJ, Goldstein SL, et al. Alpha 3 beta 1 integrin has a crucial role in kidney and lung organogenesis. Development. 1996;122:3537-3547.
43. Reiser J, Oh J, Shirato l, et al. Podocyte migration during nephrotic syndrome requires a coordinated interplay between cathepsin L and alpha3 integrin. J Biol Chem. 2004;279:34827-34832.
44. Reiser J, Polu KR, Moller CC, et al. TRPC6 is a glomerular slit diaphragm- associated channel required for normal renal function. Nat Genet. 2005;37:739-744.
45. Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science. 2005;308:1801-1804.
46. Moller CC, Wei C, Altintas MM, et al. lnduction of TRPC6 channel in acquired forms of proteinuric kidney disease. J Am Soc Nephrol. 2007;18:29-36.
47. Huber TB, Schermer B, Benzing T. Podocin organizes ion channel-lipid supercomplexes: implications for mechanosensation at the slit diaphragm. Nephron Exp Nephrol. 2007;106:e27-e31.
48. Barri YM, Munshi NC, Sukumalchantra S, et al. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004;65:634-641.
49. Markowitz GS, Appel GB, Fine PL, et al. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164-1172.
50. Rogers MJ, Gordon S, Benford HL, et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961-2978.
51. Takeda T, McQuistan T, Orlando RA, Farquhar MG. Loss of glomerular foot processes is associated with uncoupling of podocalyxin from the actin cytoskeleton. J Clin Invest. 2001;108:289-301.
52. Reiser J, Mundel P. Danger signaling by glomerular podocytes defines a novel function of inducible B7-1 in the pathogenesis of nephrotic syndrome. J Am Soc Nephrol. 2004;15:2246-2248.
53. Reiser J, von Gersdorff G, Loos M, et al. Induction of B7-1 in podocytes is associated with nephrotic syndrome. J Clin Invest. 2004;113:1390-1397.
54. Hinkes B, Wiggins RC, Gbadegesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet. 2006;38:1397-1405.
55. Gbadegesin R, Hinkes BG, Hoskins BE, et al. Mutations in PLCE1 are a major cause of isolated diffuse mesangial sclerosis (IDMS). Nephrol Dial Transplant. 2008;23:1291-1297.
56. Barisoni L, Diomedi-Camassei F, Santorelli FM, et al. Collapsing glomerulopathy associated with inherited mitochondrial injury. Kidney Int. 2008;74:237-243.
57. Hagiwara M, Yamagata K, Capaldi RA, Koyama A. Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis. Kidney Int. 2006;69:1146-1152.
58. Holthofer H, Kretzler M, Haltia A, et al. Altered gene expression and functions of mitochondria in human nephrotic syndrome. FASEB J.1999;13:523-532.
59. Solin ML, Pitkanen S, Taanman JW, Holthofer H. Mitochondrial dysfunction in congenital nephrotic syndrome. Lab Invest. 2000;80:1227-1232.
60. Sauter M, Julg B, Porubsky S, et al. Nephrotic-range proteinuria following pamidronate therapy in a patient with metastatic breast cancer: mitochondrial toxicity as a pathogenetic concept? Am J Kidney Dis. 2006;47:1075-1080.
61. Moeller MJ, Holzman LB. Imaging podocyte dynamics. Nephron Exp Nephrol. 2006;103:e69-e74.
62. O'Rourke B, Cortassa S, Aon MA. Mitochondrial ion channels: gatekeepers of life and death. Physiology (Bethesda). 2005;20:303-315.
63. Berkovic SF, Dibbens LM, Oshlack A, et al. Array-based gene discovery with three unrelated subjects shows SCARB2/LIMP-2 deficiency causes myoclonus epilepsy and glomerulosclerosis. Am J Hum Genet. 2008;82:673-684.
64. Liapis H. Childhood nephrotic syndrome: from generic to molecular diagnosis. Pediatr Dev Pathol. 2008;11:154-163.
65. Albaqumi M, Barisoni L. Current views on collapsing glomerulopathy. J Am Soc Nephrol. 2008;19:1276-1281.
66. Stokes MB, Valeri AM, Markowitz GS, D'Agati VD. Cellular focal segmen- tal glomerulosclerosis: clinical and pathologic features. Kidney Int. 2006;70:1783-1792.
67. Thomas DB, Franceschini N, Hogan SL, etal. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int. 2006;69:920-926.
68. Stillman IE, Karumanchi SA. The glomerular injury of preeclampsia. J Am Soc Nephrol. 2007;18:2281-2284.
69. Eremina V, Jefferson JA, Kowalewska J, et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med. 2008;358:1129-1136.
70. Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest. 2003;111:649-658.
71. Nagai Y, Arai H, Washizawa Y, et al. FSGS-like lesions in pre-eclampsia. Clin Nephrol. 1991;36:134-140.
72. Howie AJ, Lee SJ, Sparke J. Pathogenesis of segmental glomerular changes at the tubular origin, as in the glomerular tip lesion. JPathol.1995;177: 191-199.
73. Haas M. The glomerular tip lesion: what does it really mean? Kidney Int. 2005;67:1188-1189.
74. Haas M, Yousefzadeh N. Glomerular tip lesion in minimal change nephropathy: a study of autopsies before 1950. Am J Kidney Dis. 2002;39:1168-1175.
75. Howie AJ, PankhurstT, Sarioglu S, Turhan N, Adu D. Evolution of nephrot- ic-associated focal segmental glomerulosclerosis and relation to the glomerular tip lesion. Kidney Int. 2005;67:987-1001.
76. Howie AJ, Ferreira MA, Majumdar A, Lipkin GW. Glomerular prolapse as precursor of one type of segmental sclerosing lesions. J Pathol. 2000;190:478-483.
77. Fine RN. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol. 2007;22:496-502.
78. Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol. 2003;23:147-160.
79. Koyama A, Fujisaki M, Kobayashi M, Igarashi M, Narita M. A glomerular permeability factor produced by human T cell hybridomas. KidneyInt. 1991;40:453-460.
80. Bertelli R, Ginevri F, Caridi G, et al. Recurrence of focal segmental glo merulosclerosis after renal transplantation in patients with mutations of podocin. Am J Kidney Dis. 2003;41:1314-1321.
81. Caridi G, Dagnino M, Sanna-Cherchi S, Perfumo F, Ghiggeri GM. Podocinrelated mechanisms in posttransplant [corrected] recurrence of focal segmental glomerulosclerosis [corrected]. Transplant Proc. 2006;38:3486-3490.
82. Avila-Casado Mdel C, Perez-Torres I, Auron A, Soto V, Fortoul TI, Herrera-Acosta J. Proteinuria in rats induced by serum from patients with collapsing glomerulopathy. Kidney Int. 2004;66:133-143.
83. Meehan SM, Pascual M, Williams WW, et al. De novo collapsing glomerulopathy in renal allografts. Transplantation. 1 998;65:1 192-1 197.
84. Moudgil A, Nast CC, Bagga A, et al. Association of parvovirus B19 infection with idiopathic collapsing glomerulopathy. Kidney Int. 2001;59:2126-2133.
85. Nadasdy T, Allen C, Zand MS. Zonal distribution of glomerular collapse in renal allografts: possible role of vascular changes. Hum Pathol. 2002;33:437-441.
86. Tumlin JA, Miller D, Near M, Selvaraj S, Hennigar R, Guasch A. A prospective, open-label trial of sirolimus in the treatment of focal segmental glo- merulosclerosis. Clin J Am Soc Nephrol. 2006;1:109-116.
87. Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis. 2007;49:310-317.
88. Fervenza FC, Fitzpatrick PM, Mertz J, et al. Acute rapamycin nephrotoxi- city in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant. 2004;19:1288-1292.
89. Cho ME, Smith DC, Branton MH, Penzak SR, Kopp JB. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2007;2:906-913.
90. Ransom RF, Lam NG, Hallett MA, Atkinson SJ, Smoyer WE. Glucocorti- coids protect and enhance recovery of cultured murine podocytes via actin filament stabilization. Kidney Int. 2005;68:2473-2483.
91. Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW. Direct effects of dexamethasone on human podocytes. Kidney Int. 2006;70:1038-1045.
92. Wada T, Pippin JW, Marshall CB, Griffin SV, Shankland SJ. Dexamethasone prevents podocyte apoptosis induced by puromycin aminonucleoside: roleofp53 and Bcl-2-related family proteins. J Am Soc Nephrol. 2005;16:2615-2625.
93. He JC, Lu TC, Fleet M, et al. Retinoic acid inhibits HIV-1-induced podocyte proliferation through the cAMP pathway. J Am Soc Nephrol. 2007;18:93-102.
94. Takano Y, Yamauchi K, Hiramatsu N, et al. Recovery and maintenance of nephrin expression in cultured podocytes and identification of HGF as a repressor of nephrin. Am J Physiol Renal Physiol. 2007;292:F1573-F1582.
95. Shibata S, Nagase M, Fujita T. Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol. 2006;17:754-764.
96. Whaley-Connell A, DeMarco VG, Lastra G, et al. Insulin resistance, oxi- dative stress, and podocyte injury: role of rosuvastatin modulation of filtration barrier injury. Am J Nephrol. 2008;28:67-75.
97. Nakajo A, Khoshnoodi J, Takenaka H, et al. Mizoribine corrects defective nephrin biogenesis by restoring intracellular energy balance. J Am Soc Nephrol. 2007;18:2554-2564.
98. Suganami T, Mukoyama M, Mori K, et al. Prevention and reversal of renal injury by leptin in a new mouse model of diabetic nephropathy. FASEB J. 2005;19:127-129.
99. Wang S, de Caestecker M, Kopp J, Mitu G, Lapage J, Hirschberg R. Renal bone morphogenetic protein-7 protects against diabetic nephropathy. J Am Soc Nephrol. 2006;17:2504-2512.
100. Mitu GM, Wang S, Hirschberg R. BMP7 is a podocyte survival factor and rescues podocytes from diabetic injury. Am J Physiol Renal Physiol. 2007;293:F1641-F1648.
101. Isermann B, Vinnikov IA, Madhusudhan T, et al. Activated protein C protects against diabetic nephropathy by inhibiting endothelial and podocyte apoptosis. Nat Med. 2007;13:1349-1358.
102. Ortmann J, Amann K, Brandes RP, et al. Role of podocytes for reversal of glomerulosclerosis and proteinuria in the aging kidney after endothelin inhibition. Hypertension. 2004;44:974-981.
103. Bridgewater DJ, Ho J, Sauro V, Matsell DG. Insulin-like growth factors inhibit podocyte apoptosis through the PI3 kinase pathway. Kidney Int. 2005;67:1308-1314.
104. Sasaki T, Jyo Y, Tanda N, et al. Changes in glomerular epithelial cells induced by FGF2 and FGF2 neutralizing antibody in puromycin aminonucleoside nephropathy. Kidney Int. 1997;51:301-309.
105. Siu B, Saha J, Smoyer WE, Sullivan KA, Brosius FC III. Reduction in po- docyte density as a pathologic feature in early diabetic nephropathy in rodents: prevention by lipoic acid treatment. BMC Nephrol. 2006;7:6.
106. Nakamura T, Ushiyama C, Shimada N, et al. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care. 2000;23:1168-1171.
107. Kriz W, Hahnel B, Rosener S, Elger M. Long-term treatment of rats with FGF-2 results in focal segmental glomerulosclerosis. Kidney Int. 1995;48:1435-1450.
108. Obligado SH, Ibraghimov-Beskrovnaya O, Zuk A, Meijer L, Nelson PJ. CDK/GSK-3 inhibitors as therapeutic agents for parenchymal renal diseases. Kidney Int. 2008;73:684-690.
109. Kopp JB, Smith MW, Nelson GW, et al. MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis. Nat Genet. 2008;40:1175-1184.